Literature DB >> 6109348

Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models.

M Stanley, A Lautin, J Rotrosen, S Gershon, D Kleinberg.   

Abstract

Metoclopramide is a substituted benzamide derivative, structurally similar to procainamide and sulpiride. In behavioral, biochemical, and neuroendocrine tests it displays classic neuroleptic dopamine (DA) antagonist properties; in contrast to other DA antagonists, it lacks potency in currently used DA receptor models. In clinical studies using low doses or dubious measures, it was considered not to be efficacious as an antipsychotic. We now find that it indeed has a clinical profile similar to known neuroleptics when used in a dose range predicted from animal models. The findings raise questions regarding the validity and universality of several predictive models, as well as hypotheses purporting to explain molecular mechanisms of action of neuroleptic agents. The drug's inactivity in receptor models suggests that an as yet unidentified DA receptor subpopulation may be important as the mediator of many DA dependent neurobiologic phenomena.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109348     DOI: 10.1007/bf00433055

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Sustained elevation of serum prolactin by metoclopramide: a clinical model of idiopathic hyperprolactinemia.

Authors:  D L Healy; H G Burger
Journal:  J Clin Endocrinol Metab       Date:  1978-05       Impact factor: 5.958

Review 2.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

3.  A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.

Authors:  P Jenner; P N Elliott; A Clow; C Reavill; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1978-01       Impact factor: 3.765

4.  The effects of standard neuroleptic compounds on the binding of 3H-spiroperidol in the striatum and mesolimbic system of the rat in vitro.

Authors:  J L Howard; B T Large; S Wedley; I A Pullar
Journal:  Life Sci       Date:  1978-08-14       Impact factor: 5.037

5.  Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs.

Authors:  P N Elliott; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1978-12       Impact factor: 3.765

6.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

7.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

8.  [Clinical and electroencephalographic effects of methoclopramide in psychiatry].

Authors:  P Borenstein; G Bles
Journal:  Therapie       Date:  1965 Jul-Aug       Impact factor: 2.070

9.  Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine.

Authors:  B Costall; R J Naylor
Journal:  Eur J Pharmacol       Date:  1976-01       Impact factor: 4.432

10.  A radioimmunoassay for human prolactin.

Authors:  P Hwang; H Guyda; H Friesen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

View more
  15 in total

1.  Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

Authors:  C A Altar; W C Boyar; A Wasley; S C Gerhardt; J M Liebman; P L Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

2.  Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study.

Authors:  J A Stamford; Z L Kruk; J Millar
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 3.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Blockade of acquisition of one-way conditioned avoidance responding by haloperidol and metoclopramide but not by thioridazine or clozapine: implications for screening new antipsychotic drugs.

Authors:  J R Blackburn; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  The inhibitory effect of metoclopramide on plasma cholinesterase activity.

Authors:  J R Kambam; W C Parris; J J Franks; B V Sastry; R Naukam; B E Smith
Journal:  Can J Anaesth       Date:  1988-09       Impact factor: 5.063

6.  Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioural screen for antipsychotic activity.

Authors:  D C Roberts; G Vickers
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.

Authors:  L A Dunn; G E Atwater; C D Kilts
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Differential reversal of various dopamine antagonists by anticholinergics in Sidman avoidance: possible relationship to adrenergic blockade.

Authors:  J M Liebman; R Neale; L Noreika; A Braunwalder
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Differential effects of sulpiride and metoclopramide on brain. Homovanillic acid levels and shuttle box avoidance after systemic and intracerebral administration.

Authors:  Y Nishibe; Y Matsuo; T Yoshizaki; M Eigyo; T Shiomi; K Hirose
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

Review 10.  The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.

Authors:  R Miller
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.